Cite
Gisclon LG, Bowen AJ, O'Reilly TE, et al. Bioequivalence of a newly developed 17 beta-estradiol tablet versus an identical reference formulation. Arzneimittelforschung. 2000;50(10):910-4doi: 10.1055/s-0031-1300314.
Gisclon, L. G., Bowen, A. J., O'Reilly, T. E., Lakewold, D., Curtin, C. R., Larson, K. L., Palmer, S. A., Natarajan, J., & Wong, F. A. (2000). Bioequivalence of a newly developed 17 beta-estradiol tablet versus an identical reference formulation. Arzneimittel-Forschung, 50(10), 910-4. https://doi.org/10.1055/s-0031-1300314
Gisclon, et al. "Bioequivalence of a newly developed 17 beta-estradiol tablet versus an identical reference formulation." Arzneimittel-Forschung vol. 50,10 (2000): 910-4. doi: https://doi.org/10.1055/s-0031-1300314
Gisclon LG, Bowen AJ, O'Reilly TE, Lakewold D, Curtin CR, Larson KL, Palmer SA, Natarajan J, Wong FA. Bioequivalence of a newly developed 17 beta-estradiol tablet versus an identical reference formulation. Arzneimittelforschung. 2000 Oct;50(10):910-4. doi: 10.1055/s-0031-1300314. PMID: 11105233.
Copy
Download .nbib